Chemical formula: C₁₃H₁₈N₂O₃ Molecular mass: 250.294 g/mol PubChem compound: 219078
Lacosamide is a functionalised amino acid. The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AX18 | Lacosamide | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VIMPAT Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VIMPAT Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VIMPAT Syrup | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VIMPAT Film-coated tablet, Treatment initiation pack | European Medicines Agency (EU) | MPI, EU: SmPC |
Lacosamide is an active ingredient of these brands:
Australia (AU)Canada (CA)Finland (FI)France (FR)Hong Kong (HK)Ireland (IE)Israel (IL)Italy (IT)Japan (JP)Mexico (MX)Netherlands (NL)New Zealand (NZ)Romania (RO)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
